KEVZARA (sarilumab), Regeneron
Indications: The treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs).
Dosage: May be used as monotherapy or in combination with methotrexate or other conventional DMARDs. 200 mg once every 2 weeks, administered as a subcutaneous injection.
Contraindications: Patients with known hypersensitivity to sarilumab or any of the inactive ingredients.